

# CHOOSING THE RIGHT ePRO MODALITY FOR YOUR STUDY

If you've decided to use ePRO, you'll now want to decide between web or app solutions, and whether participants should use a smartphone or tablet provided for the study or use their own (bring your own device - BYOD).

The following steps will help you decide.



## 01 WHERE WILL ePRO DATA BE COLLECTED?

Will ePRO data be collected at home, at the trial site, or on the go?

For site-based collection, use provisioned devices with web or app solutions; web is often preferred for large sites with many patients and needing multiple devices. For at-home collection, app enables offline capture so that data can be collected if connectivity is unavailable. Web provides immediate access to the data entered and may also be valuable in long studies or studies with infrequent completion.



## 02 HOW FREQUENTLY AND FOR HOW LONG WILL DATA BE COLLECTED AT HOME?

Will data be collected multiple times per day, daily, weekly, monthly?

For frequent data collection (multiple times per day or daily), both app and web solutions may be suitable, although web may be less desirable if completion windows are short and there are concerns over connectivity. If completion windows are short, then use an offline app solution to avoid missing data.

Less frequent collection, with longer completion windows may make web collection an attractive option.

How long is the data collection period?

For long-term studies, app updates and mid-study device changes may make web collection through a browser an attractive option when using BYOD.



## 04 CONSIDER YOUR PATIENT POPULATION

Select a solution that aligns with the needs of your patient demographic. For instance, cancer patients who require flexibility in completing patient-reported outcomes (PROs) might favor the Bring Your Own Device (BYOD) approach, as it allows them to use their personal devices when they feel well enough. Conversely, in populations where smartphone ownership is less common, a provisioned device solution may be more suitable.

For further guidance on addressing diverse population needs, refer to our guide on optimizing electronic patient-reported outcomes (ePRO).



## 03 WHO WILL THE DATA BE COLLECTED FROM, AND WHERE ARE THEY LOCATED?

Consider the population characteristics, geographic locations, and language requirements of the study. For rural and remote communities or areas with connectivity challenges, app-based solutions that enable offline data entry are preferred.



### A NOTE ON SUPPORTING EVIDENCE OF YOUR MODALITY CHOICE

There are two types of evidence typically required.

**Usability evidence** - evidence that the solution chosen is usable in a population representative of the study population.

**Measurement comparability** - There is now **sufficient evidence already published** to show that measures migrated from paper formats to screen-based formats have consistent measurement properties, when measures use standard response scales and implementation best practice standards are followed.

Check with Signant to ensure you have the evidence needed.



## 05 ENGAGE WITH SIGNANT TO HELP CHOOSE THE BEST ePRO MODALITY FOR YOUR STUDY

Considering these factors, you can select the most suitable ePRO modality for your clinical trial, ensuring data quality, participant convenience, and addressing study requirements.

Engage with Signant's eCOA scientific and medical experts to help determine the best approach for your study.



### WEB

Accessed through a web browser on an internet-connected smartphone, tablet or computer

#### Strengths

- ✓ Can be accessed using any device
- ✓ Does not require a download

#### Limitations

- × Cannot be used without connectivity
- × Less precise control over exact layout/appearance

#### When to use

- Long duration studies with less frequent data collection
- Countries with good connectivity
- Studies with longer completion windows
- Site-based data collection



### APP

Accessed using an app on a smartphone or tablet

#### Strengths

- ✓ Patients can enter data with or without connectivity
- ✓ More precise control of layout/appearance
- ✓ More able to use device native features, e.g., camera.

#### Limitations

- × Requires a download when using BYOD

#### When to use

- Suitable for any study, especially home-based data collection

### WHO IS SIGNANT HEALTH?

Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 25 years, over 600 sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at [www.signanthealth.com](http://www.signanthealth.com).